EHA 2024 | Inotuzumab-containing bridging therapy in patients with R/R B-ALL receiving obe-cel
Jae Park, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the impact of inotuzumab-containing bridging therapy on post-CAR T-cell therapy outcomes in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) receiving obecabtagene autoleucel (obe-cel). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Autolus Therapeutic, Genentech, Inc., Fate Therapeutics, Servier, Incyte, Takeda, Sobi; Consultancy: Curocell, Affyimmune, Amgen, Artiva Biotherapeutics, Bright Pharmacetuicals, Be Biopharma, BeiGene, Servier, Allogene, Intella, Takeda, Sobi, Pfizer, Kite, Minerva Bio, Synthekine; Current holder of stock options in a privately-held company: Artiva Biotherapeutics; Membership on Board of Directors or advisory committee: Artiva Biotherapeutics, Allogene, GC Cell.
